Coen D A Stehouwer Selected Research

Nitroprusside (Sodium Nitroprusside)

3/2015	Growth and endothelial function in the first 2 years of life.
9/2008	Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
7/2007	Urinary cortisol is inversely associated with capillary recruitment in women: a potential explanation for the cortisol-blood pressure relationship.
11/2004	Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy.
6/2004	Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance.
5/2002	Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Coen D A Stehouwer Research Topics

Disease

115	Type 2 Diabetes Mellitus (MODY) 11/2022 - 02/2002
76	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 04/2002
61	Inflammation (Inflammations) 01/2022 - 03/2002
50	Insulin Resistance 12/2021 - 02/2002
29	Atherosclerosis 01/2022 - 03/2002
28	Obesity 04/2022 - 03/2002
28	Hypertension (High Blood Pressure) 01/2022 - 04/2002
24	Albuminuria 01/2022 - 10/2002
21	Prediabetic State (Prediabetes) 01/2022 - 09/2009
18	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 01/2005
16	Hyperglycemia 01/2018 - 08/2002
15	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 10/2002
13	Hyperemia 01/2022 - 05/2002
11	Non-alcoholic Fatty Liver Disease 04/2022 - 04/2007
10	Glucose Intolerance 01/2022 - 07/2002
10	Chronic Renal Insufficiency 01/2019 - 01/2007
8	Weight Loss (Weight Reduction) 08/2022 - 01/2018
8	Necrosis 04/2012 - 12/2003
8	Vascular Diseases (Vascular Disease) 04/2010 - 05/2003
7	Body Weight (Weight, Body) 01/2022 - 12/2002
7	Renal Insufficiency (Renal Failure) 05/2020 - 11/2003
7	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 05/2002
7	Birth Weight (Birth Weights) 03/2015 - 12/2002
7	Chronic Kidney Failure (Chronic Renal Failure) 03/2009 - 09/2002
6	Diabetes Mellitus 01/2021 - 05/2002
6	Stroke (Strokes) 01/2018 - 05/2006
6	Hyperinsulinism (Hyperinsulinemia) 08/2010 - 05/2002
5	Weight Gain 03/2022 - 12/2002
5	Abdominal Obesity 01/2022 - 05/2009
5	Overweight 01/2021 - 11/2014
5	Myocardial Infarction 01/2018 - 05/2006
5	Coronary Disease (Coronary Heart Disease) 01/2018 - 09/2003
5	Hyperhomocysteinemia 12/2011 - 09/2002
4	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 08/2002
4	Diabetic Angiopathies (Diabetic Angiopathy) 01/2020 - 05/2002
4	Cerebral Small Vessel Diseases 01/2020 - 01/2017
4	Diabetes Complications 01/2019 - 03/2011
3	Neoplasms (Cancer) 03/2022 - 01/2015

Drug/Important Bio-Agent (IBA)

105	Glucose (Dextrose)FDA LinkGeneric 08/2022 - 04/2002
45	Insulin (Novolin)FDA Link 01/2022 - 03/2002
40	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2005
30	LipidsIBA 04/2022 - 08/2002
23	Advanced Glycation End ProductsIBA 01/2021 - 03/2004
23	C-Reactive ProteinIBA 11/2018 - 04/2002
23	HomocysteineIBA 10/2012 - 02/2002
20	Triglycerides (Triacylglycerol)IBA 01/2022 - 04/2002
20	Retinaldehyde (Retinal)IBA 01/2022 - 04/2008
18	CholesterolIBA 04/2022 - 10/2002
17	HDL CholesterolIBA 07/2021 - 04/2002
16	Metformin (Glucophage)FDA LinkGeneric 10/2022 - 12/2002
12	Pyruvaldehyde (Methylglyoxal)IBA 11/2022 - 04/2008
12	von Willebrand FactorIBA 01/2022 - 04/2002
12	SelectinsIBA 01/2022 - 03/2004
12	Antihypertensive Agents (Antihypertensives)IBA 10/2020 - 04/2007
11	AlbuminsIBA 01/2018 - 04/2002
11	Immunoglobulin M (IgM)IBA 01/2016 - 08/2002
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2003
10	CreatinineIBA 01/2018 - 04/2002
9	LDL CholesterolIBA 07/2021 - 10/2002
9	N(6)-carboxymethyllysine (carboxymethyllysine)IBA 01/2020 - 03/2004
9	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 03/2015 - 04/2002
8	E-SelectinIBA 01/2022 - 03/2004
8	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2020 - 05/2008
8	EnzymesIBA 01/2019 - 12/2003
8	Folic Acid (Vitamin M)FDA LinkGeneric 01/2019 - 09/2002
8	AdiponectinIBA 11/2018 - 06/2003
8	AdipokinesIBA 07/2014 - 05/2005
7	pentosidineIBA 10/2021 - 03/2009
7	Acetylcholine (Acetylcholine Chloride)FDA Link 03/2015 - 05/2002
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2010 - 05/2002
6	Blood Glucose (Blood Sugar)IBA 01/2022 - 05/2012
6	FructoseIBA 01/2022 - 04/2017
6	Complement System Proteins (Complement)IBA 03/2021 - 12/2012
6	Uric Acid (Urate)IBA 01/2018 - 11/2014
6	Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric 03/2015 - 05/2002
6	Serum Amyloid A Protein (Serum Amyloid A)IBA 03/2015 - 02/2011
5	Complement C3 (C3 Complement)IBA 01/2022 - 04/2011
5	Vitamin D FDA LinkGeneric 12/2020 - 11/2009
5	Interleukin-8 (Interleukin 8)IBA 03/2015 - 03/2012
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2015 - 02/2006
5	Interleukin-6 (Interleukin 6)IBA 11/2014 - 09/2006
5	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 07/2012 - 09/2003
5	Plasminogen Activator Inhibitor 1IBA 03/2012 - 06/2005
4	SodiumIBA 08/2022 - 11/2014
4	Alanine Transaminase (SGPT)IBA 04/2022 - 04/2007
4	Biological ProductsIBA 01/2022 - 11/2011
4	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2021 - 02/2003
4	Cystatin CIBA 01/2018 - 01/2015
4	ThrombomodulinIBA 03/2015 - 03/2004
4	Receptor for Advanced Glycation End ProductsIBA 06/2014 - 04/2008
4	Fibrinogen (Factor I)FDA Link 10/2013 - 01/2005
4	Nitric Oxide Synthase (NO Synthase)IBA 07/2012 - 09/2003
4	S-AdenosylhomocysteineIBA 03/2012 - 08/2004
4	DNA (Deoxyribonucleic Acid)IBA 08/2008 - 05/2003
4	Methionine (L-Methionine)FDA Link 05/2005 - 08/2004
3	Complement Factor D (Factor D)IBA 01/2022 - 12/2018
3	Vitamin E FDA LinkGeneric 01/2022 - 06/2007

Therapy/Procedure

18	Therapeutics 03/2022 - 12/2002
10	Glycemic Control 01/2021 - 12/2002
4	Hormone Replacement Therapy (Therapy, Hormone Replacement) 09/2003 - 05/2002